EIPICO’s consolidated profit grows 20.9% YoY in Q1
Updated 5/25/2022 1:40:00 PM
Arab Finance: The Egyptian International Pharmaceutical Industries Company (EIPICO) (PHAR) reported a 20.9% year-on-year (YoY) increase in consolidated net profit after tax for the first quarter (Q1) of 2022, according to the consolidated financial income statement filed to the Egyptian Exchange (EGX) on May 25th.
The company recorded a consolidated net profit after tax of EGP 173.68 million in Q1 2022, compared to EGP 143.54 million in Q1 2021.
Moreover, the company generated consolidated net sales of EGP 927.37 million in the three-month period ended March 31st, growing from EGP 800.38 million in the same period last year.
As per EIPICO’s standalone financial income statement, the company achieved a standalone net profit after tax of EGP 185.89 million in Q1 2022, up from EGP 167.19 million in the year-ago quarter.
EIPICO is an Egypt-based public shareholding company that operates in the pharmaceutical industry. It is a manufacturer and exporter of pharmaceuticals and holds license agreements with a group of international.
